Update of our Target 96 Development panel (Oct 2020)
In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a change has been made to the Olink®Target 96 Development panel. A high performance assay with a possible role in bone remodeling, metabolic diseases and tumorigenesis has been selected from our customer driven wish-list. This has been incorporated into an updated version of the panel, replacing one assay from the previous version. For more details please visit the panel update page.
Can we help you?
Let us know how best to contact you below (email or phone). PLEASE NOTE, include your international dialing code when submitting your phone number!